Product Description
TL1A Antibody [TLRM1-1] | 34-047 | ProSci
Host: Mouse
Reactivity: Human
Homology: N/A
Immunogen: A human partial recombinant protein was used as the immunogen for this TL1A antibody.
Research Area: Apoptosis, Neuroscience
Tested Application: WB, Flow, IF, IHC
Application: Flow Cytometry: 0.5-1ug/10^6 cells
IF: 1-2 ug/ml
Western blot: 1-2 ug/ml
IHC (FFPE) : 0.5-1 ug/ml (1)
The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the TL1A antibody to be titered up or down for optimal performance.
1. Staining of FFPE tissue requires boiling sections in 10mM Tris with 1mM EDTA, pH9, for 10-20 min followed by cooling at RT for 20 min.
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: Protein G affinity chromatography
Clonality: Monoclonal
Clone: TLRM1-1
Isotype: IgG 1, kappa
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.
Alternate Name: TL1A Antibody: TL1, TL1A, VEGI, VEGI192A, TL1, Tumor necrosis factor ligand superfamily member 15, TNF ligand-related molecule 1
User Note: Optimal dilutions for each application to be determined by the researcher
BACKGROUND: TNF ligand-related molecule 1 is an anti-angiogenic cytokine that is also called Tumor necrosis factor superfamily, member 15 (TNFSF15) and Vascular endothelial growth inhibitor (VEGI/VEGI192A) . This protein is abundantly expressed in endothelial cells, but is not expressed in either B or T cells. The expression of this protein is inducible by TNF and IL-1 alpha. This cytokine is a ligand for receptor TNFRSF25 and decoy receptor TNFRSF21/DR6. It can activate NF-kappaB and MAP kinases, and acts as an autocrine factor to induce apoptosis in endothelial cells. This cytokine is also found to inhibit endothelial cell proliferation, and thus may function as an angiogenesis inhibitor. Reduced expression of TL1A has been reported as a marker of poor prognosis in breast cancer.